Top

Hepatology International

Published in:

01-06-2009 | Review Article

The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B

Author: Brian J. McMahon

Published in: Hepatology International | Issue 2/2009

Abstract

Background

Chronic infection with hepatitis B virus (HBV) is associated with a high lifetime risk of developing hepatocellular carcinoma (HCC) and cirrhosis of the liver.

Purpose

To review the studies published to date regarding the association of HBV genotypes and subgenotypes in the development of adverse sequelae from HBV.

Methods

Review of the literature for articles describing studies of HBV genotype/subgenotypes and development of HCC, cirrhosis, and liver-related death.

Results

Eight genotypes of HBV (A through H), which differ from each other in viral genome sequence by more than 8%, and multiple subgenotypes, which differ from each other by 4–8% have been identified. Recently, studies investigating the association between the risks of developing HCC and cirrhosis by specific HBV genotypes and subgenotypes have reported marked differences in outcome. Certain HBV genotypes and subgenotypes, including genotype C, B2-5, and F1, appear to be associated with a higher risk of developing HCC, and others, including genotypes B1, B6, and A2, appear to be associated with a lower risk of complications of HBV. Our understanding of the role of HBV genotypes and subgenotypes on the outcome of HBV infection is limited, as few population-based prospective studies have been performed and most studies compare only the outcome in areas where two genotypes predominate whereas others have not examined subgenotypes.

Conclusions

Studies to date suggest that HBV genotypes/subgenotypes have important influences on the outcome of chronic HBV infection, but more population-based prospective studies examining multiple genotypes are needed.

Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11(2):97–107. doi:10.1046/j.1365-2893.2003.00487.x.PubMedCrossRef

Lok ASK, McMahon B. AASLD practice guidelines: chronic hepatitis B. Hepatology 2007;45:507–539. doi:10.1002/hep.21513.PubMedCrossRef

Fung SK, Lok A. Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection? Hepatology 2004;40(4):790–792.PubMed

Kramvis A, Kew M. Relationships of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy. J Viral Hepat 2004;12:456–464. doi:10.1111/j.1365-2893.2005.00624.x.CrossRef

Kramvis A, Kew M, Francois G. Hepatitis B virus genotypes. Vaccine 2005;23:2409–2423. doi:10.1016/j.vaccine.2004.10.045.PubMedCrossRef

Miyakawa Y, Mizokami M. Classifying hepatitis B virus genotypes. Intervirology 2003;46:329–338. doi:10.1159/000074988.PubMedCrossRef

Schaefer S. Hepatitis B virus: significance of genotypes. J Viral Hepat 2005;12:111–124. doi:10.1111/j.1365-2893.2005.00584.x.PubMedCrossRef

Chu CJ, Keefe E, Han SH, Perrillo RP, Min AD, Soldevila-Pico C, et al. Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology 2003;125:444–451. doi:10.1016/S0016-5085(03)00895-3.PubMedCrossRef

Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005;54(RR-16):1–31.PubMed

10.

Beasley RP, Hwang LY, Lee GC, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983;2(8359):1099–1102. doi:10.1016/S0140-6736(83)90624-4.PubMedCrossRef

11.

Beasley RP, Hwang LY, Lin CC, et al. Incidence of hepatitis B virus infections in preschool children in Taiwan. J Infect Dis 1982;146(2):198–204.PubMed

12.

McMahon BJ, Alward WL, Hall DB, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985;151(4):599–603.PubMed

13.

Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2006;55(RR16):1–25.PubMed

14.

Mast EE, Alter MJ, Margolis HS. Strategies to prevent and control hepatitis B and C virus infections: a global perspective. Vaccine 1999;17(13–14):1730–1733. doi:10.1016/S0264-410X(98)00415-0.PubMedCrossRef

15.

Livingston SE, Simonetti J, Bulkow L, Homan CE, Snowball MM, Cagle HH, et al. Clearance of Hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D and F. Gastroenterology 2007;133:1452–1457. doi:10.1053/j.gastro.2007.08.010.PubMedCrossRef

16.

Kew MC, Kramvis A, Yu MC, Arakawa K, Hodkinson J. Increased hepatocarcinogenic potential of hepatitis B virus genotype in Bantu-speaking sub-Saharan Africans. J Med Virol 2005;75:513–521. doi:10.1002/jmv.20311.PubMedCrossRef

17.

Kramvis A, Kew M, Bukofzer S. Hepatitis B precore mutants in serum and liver of Southern African Blacks with hepatocellular carcinoma. J Hepatol 1998;28:132–141. doi:10.1016/S0168-8278(98)80212-2.PubMedCrossRef

18.

Kimbi G, Kramvis A, Kew M. Distinctive sequence characteristics of subgenotype A1 isolates of hepatitis B virus from South Africa. J Gen Virol 2004;85:1211–1220. doi:10.1099/vir.0.19749-0.PubMedCrossRef

19.

Norder H, Courouce A, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK, et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 2004;47(6):289–309. doi:10.1159/000080872.PubMedCrossRef

20.

Langer BCA, Frosner G, Von Brunn A. Epidemiological study of viral hepatitis types A, B, C, D, and E among Inuits in West Greenland. J Viral Hepat 1997;4:339–349. doi:10.1046/j.1365-2893.1997.00063.x.PubMedCrossRef

21.

Livingston SE, Simonetti J, McMahon B, Bulkow L, Hurlburt KJ, Homan CE, et al. Hepatitis B virus genotypes in Alaska Native People with hepatocellular carcinoma: preponderance of genotype F. J Infect Dis 2007;195:5–11. doi:10.1086/509894.PubMedCrossRef

22.

Sanchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodes J. Influence of hepatitis B viral genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 2002;123:1848–1856. doi:10.1053/gast.2002.37041.PubMedCrossRef

23.

Kurbanov F, Tanaka Y, Fujiqara K, et al. A new subtype (subgenotype) Ac (A3) of hepatitis B virus and recombination between genotypes A and E in Cameroon. J Gen Virol 2005;86:2047–2056. doi:10.1099/vir.0.80922-0.PubMedCrossRef

24.

Sakamoto T, Tanaka YSJ, Osiowy C, Børresen ML, Koch A, Kurbanov F, et al. Classification of hepatitis B virus genotype B into two major forms based on characterization of a novel subgenotype in the Arctic indigenous populations. J Infect Dis 2007;196:1487–1492. doi:10.1086/523111.PubMedCrossRef

25.

Kobayashi M, Fumitaka S, Akuta N, Tsubota A, Ikeda K, Arase Y, et al. Virological differences between patients infected with subtypes Ba and Bj or hepatitis B virus genotype B. J Gastroenterol Hepatol 2005;20:570–576. doi:10.1111/j.1440-1746.2005.03798.x.PubMedCrossRef

26.

Saugauchi F, Orito E, Ichida T, Kato H, Sakugawa H, Kakumu S, et al. Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. Gastroenterology 2003;124:925–932. doi:10.1053/gast.2003.50140.CrossRef

27.

Ozasa A, Tanaka Y, Orito E, Sugiyama M, Kang JH, Hige S, et al. Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology 2006;44:326–334. doi:10.1002/hep.21249.PubMedCrossRef

28.

Orito E, Mizokami M. Hepatitis B virus genotypes and hepatocellular carcinoma in Japan. Intervirology 2003;46:408–412. doi:10.1159/000075000.PubMedCrossRef

29.

Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B virus genotypes and hepatocellular carcinoma in Taiwan. Intervirology 2003;46:400–407. doi:10.1159/000074999.PubMedCrossRef

30.

Chen HC, Eng HL, Lee CM, Fang YK, Kuo FY, Lu SN, et al. Correlations between hepatitis B virus genotype and cirrhotic or non-cirrhotic hepatoma. Hepatogastroenterology 2004;51:552–555.PubMed

31.

Kao JH, Chen PJ, Lai MY, Chen DS. Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. J Clin Microbiol 2002;40:1207–1209. doi:10.1128/JCM.40.4.1207-1209.2002.PubMedCrossRef

32.

Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers. J Med Virol 2004;72:363–369. doi:10.1002/jmv.10534.PubMedCrossRef

33.

Chan HL, Hui AY, Wong ML, Tse AM, Hung LC, Wong VW, et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004;53:1494–1498. doi:10.1136/gut.2003.033324.PubMedCrossRef

34.

Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000;118:554–559. doi:10.1016/S0016-5085(00)70261-7.PubMedCrossRef

35.

Lee CM, Chen CH, Lu SN, Tung HD, Chou WJ, Wang JH, et al. Prevalence and clinical implications of hepatitis B virus genotypes in southern Taiwan. Scand J Gastroenterol 2003;38:95–101. doi:10.1080/00365520310003048.PubMedCrossRef

36.

Tangkijvanich P, Mahachai V, Komolmit P, Fongsarun J, Theamboonlers A, Poovorawan Y. Hepatitis B virus genotypes and hepatocellular carcinoma in Thailand. World J Gastroenterol 2005;11(15):2238–2243.PubMed

37.

Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003;124:327–334. doi:10.1053/gast.2003.50053.PubMedCrossRef

38.

Chu CM, Laiw YF. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol 2005;43:411–417. doi:10.1016/j.jhep.2005.03.018.PubMedCrossRef

39.

Sumi H, Yokosuka O, Seki N, Arai M, Imazeki F, Kurihara T, et al. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 2003;37:19–26. doi:10.1053/jhep.2003.50036.PubMedCrossRef

40.

Watanabe K, Takahashi T, Takahashi S, Okoshi S, Ichida T, Aoyagi Y. Comparative study of genotype B and C hepatitis B virus-induced chronic hepatitis in relation to the basic core promoter and precore mutations. J Gastroenterol Hepatol 2005;20:441–449. doi:10.1111/j.1440-1746.2004.03572.x.PubMedCrossRef

41.

Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005;97:265–272.PubMedCrossRef

42.

Yuen MF, Sablon E, Yuan HJ, Wong DKH, Hui CL, Wong BCY, et al. Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma. Hepatology 2003;37:562–567. doi:10.1053/jhep.2003.50098.PubMedCrossRef

43.

Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295(1):65–73. doi:10.1001/jama.295.1.65.PubMedCrossRef

44.

Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130(3):678–686. doi:10.1053/j.gastro.2005.11.016.PubMedCrossRef

45.

Chan HL, Tse AM, Mo F, Koh J, Wong VWS, Wong GLH, et al. High viral load and hepatitis B virus subgenotype Ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol 2008;26(2):177–182. doi:10.1200/JCO.2007.13.2043.PubMedCrossRef

46.

Naoumov NV, Schneider R, Grotzinger T, et al. Precore mutant hepatitis B virus infection and liver disease. Gastroenterology 1992;102:538.PubMed

47.

McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis 2005;25(Suppl 1):3–8. doi:10.1055/s-2005-915644.PubMedCrossRef

48.

Zacharakis GH, Koskinas J, Kotsiou S, Papoutselis M, Tzara F, Vafeiadis N, et al. Natural history of chronic HBV infection: a cohort with up to 12 years follow-up in North Greece (part of the Interreg I-II/EC-Project). J Med Virol 2005;77:173–179. doi:10.1002/jmv.20434.PubMedCrossRef

49.

Grandjacques C, Pradat P, Stuyver L, et al. Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. J Hepatol 2000;33(3):430–439. doi:10.1016/S0168-8278(00)80279-2.PubMedCrossRef

50.

Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001;34(4 pt 1):617–624. doi:10.1053/jhep.2001.27834.PubMedCrossRef

51.

Brunetto MR, Oliveri F, Coco B, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002;36(2):263–270. doi:10.1016/S0168-8278(01)00266-5.PubMedCrossRef

52.

Wai CT, Fontana RJ, Polson J, Hussain M, Shakil AP, Han SH, et al. Clinical outcome and virological characteristics of hepatitis B-related acute liver failure in the United States. J Viral Hepat 2005;12:192–198. doi:10.1111/j.1365-2893.2005.00581.x.PubMedCrossRef

53.

Thukar V, Guptan RC, Kazim SN, Malhotra V, Sarin SK. Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent. J Gastroenterol Hepatol 2002;17(2):165–170. doi:10.1046/j.1440-1746.2002.02605.x.CrossRef

54.

Hurlburt KJ, McMahon BJ, Simonetti J, Livingston SE, Bulkow LR, Snowball MM, et al. Hepatitis B-associated vasculitis in Alaska Natives: viral genotype, clinical and serologic outcome. Liver Int 2007;27:627–632. doi:10.1111/j.1478-3231.2007.01473.x.PubMedCrossRef

55.

Suzuki S, Sugauchi F, Orito E, Kato H, Usuda S, Siransy L, et al. Distribution of hepatitis B virus (HBV) genotypes among HBV carriers in the Cote d’Ivoire: complete genome sequence and phylogenetic relatedness of HBV genotype E. J Med Virol 2003;69:459–465. doi:10.1002/jmv.10331.PubMedCrossRef

56.

Bekondi C, Olinger CM, Boua N, Talmarmin A, Muller CP, Le Foau A, et al. Central African Republic is part of the West African hepatitis B virus genotype E crescent. J Gen Virol 2007;88(10):2686–2695. doi:10.1099/vir.0.83102-0.CrossRef

57.

Mulders MN, Vernard V, Njayou M, Edorh P, Oyefolu AOB, Kehinde MO, et al. Low genetic diversity despite hyperenemicity of hepatitis B virus throughout West Africa. J Infect Dis 2004;190:400–408. doi:10.1086/421502.PubMedCrossRef

58.

Stuyver L, De Gendt S, Van Geyt C, Zoulim F, Fried M, Schinazi RF, et al. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol 2000;81:61–74.

59.

Kato H, Orito E, Gish RG, Bzowej N, Newsom M, Sugauchi F, et al. Hepatitis B e antigen in sera from individuals infected with hepatitis B virus of genotype G. Hepatology 2002;35:922–929. doi:10.1053/jhep.2002.32096.PubMedCrossRef

60.

Chudy M, Schimdt M, Czudai V, Scheiblauer H, Nick S, Moseback M, et al. Hepatitis B virus genotype G monoinfection and its transmission by blood components. Hepatology 2006;44:99–107. doi:10.1002/hep.21220.PubMedCrossRef

61.

Suygiyama M, Tanaka Y, Sakamoto T, Maruyama I, Shimada T, Takahashi S, et al. Early dynamics of hepatitis B virus in chimeric mice carrying human hepatocytes monoinfected or coinfected with genotype G. Hepatology 2007;45:929–937. doi:10.1002/hep.21584.CrossRef

62.

Lacombe K, Massari V, Girard PM, Serfaty L, Gozlan J, Pialoux G, et al. Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV. AIDS 2006;20(3):419–427. doi:10.1097/01.aids.0000200537.86984.0e.PubMedCrossRef

63.

Devesa M, Rodriguez C, Leon G, Liprandi F, Pujol FH. Clade analysis and surface antigen polymorphism of hepatitis B virus American genotypes. J Med Virol 2004;72:377–384. doi:10.1002/jmv.20015.PubMedCrossRef

64.

Devesa M, Loureiro CL, Rivas Y, Monsalve F, Cardona N, Duarte MC, et al. Subgenotype diversity of hepatitis B virus American genotype F in Amerindians from Venezuela and the general population of Colombia. J Med Virol 2008;80(1):20–26. doi:10.1002/jmv.21024.PubMedCrossRef

65.

Quintero A, Uzcategui N, Loureiro CL, Villegas L, Illarramendi X, Guevara ME, et al. Hepatitis delta virus genotypes I and III circulate associated with hepatitis B virus genotype F in Venezuela. J Med Virol 2001;64:356–359. doi:10.1002/jmv.1058.PubMedCrossRef

66.

Devesa M, Pujol FH. Hepatitis B virus genetic diversity in Latin America. Virus Res 2007;127:177–184. doi:10.1016/j.virusres.2007.01.004.PubMedCrossRef

67.

Arauz-Ruiz P, Norder H, Robertson BH, Magnius LO. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol 2002;83:2059–2073.PubMed

68.

Kay A, Zoulim F. Hepatitis B virus genetic variability and evolution. Virus Res 2007;127:164–176. doi:10.1016/j.virusres.2007.02.021.PubMedCrossRef

69.

Toan NI, Song LH, Kremsner PG, Duy DN, Binh VQ, Koeberlein B, et al. Impact of the hepatitis B virus genotype and genotype mixtures on the course of liver disease in Vietnam. Hepatology 2006;43:1375–1384. doi:10.1002/hep.21188.PubMedCrossRef

Title: The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B
Author: Brian J. McMahon
Publication date: 01-06-2009
Publisher: Springer-Verlag
Published in: Hepatology International / Issue 2/2009
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-008-9112-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2009

Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL)

Association of IL-18 promoter polymorphism with liver disease severity in HCV-infected patients

Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B

Systemic and pulmonary hemodynamics in patients with extrahepatic portal vein obstruction is similar to compensated cirrhotic patients

Induction of tropomyosin during hepatic stellate cell activation and the progression of liver fibrosis

Well-differentiated hepatocellular carcinoma smaller than 15 mm in diameter totally eradicated with percutaneous ethanol injection instead of radiofrequency ablation

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage